Kerry Rogers, MD
Hematology · Columbus, OHNPI 1659534246
Payments from drug & device makers
Across 358 payments — averaging $110,660 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21.6M
- Pharmacyclics LLC, An Abbvie Company$11.3M
- AstraZeneca$5.1M
- Acerta Pharma LLC$829K
- Genentech, Inc.$613K
- Janssen Research & Development, LLC$85K
- plus $180K from 15 others
Across 1 payment — averaging $407.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$407
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 162 | $21,570,304 |
| Pharmacyclics LLC, An Abbvie Company | 52 | $11,267,108 |
| AstraZeneca | 14 | $5,072,205 |
| Acerta Pharma LLC | 13 | $829,327 |
| Genentech, Inc. | 19 | $613,244 |
| Janssen Research & Development, LLC | 10 | $84,688 |
| Eli Lilly | 3 | $54,421 |
| Sanofi US Services Inc. | 16 | $41,589 |
| Rigel Pharmaceuticals, Inc. | 11 | $18,869 |
| Astrazeneca UK Limited | 6 | $16,440 |
| Lilly USA, LLC | 5 | $11,733 |
| Beigene USA, Inc. | 7 | $7,317 |
| Genentech USA, Inc. | 12 | $7,308 |
| Johnson & Johnson | 6 | $6,610 |
| Novartis | 4 | $5,191 |
| Innate Pharma, Inc | 1 | $3,300 |
| Beone Medicines USA, Inc. | 4 | $2,573 |
| Gilead | 1 | $2,080 |
| Janssen Scientific Affairs, LLC | 1 | $1,515 |
| Sanofi | 10 | $515 |
| Sobi, Inc | 1 | $51 |
How this compares
$39,616,388 in reported general payments places this provider in the 95th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Columbus
- Jennifer WoyachColumbus$406.1M
- Uma BorateColumbus$23.8M
- Kami MaddocksColumbus$14.2M
- Naresh BummaColumbus$4.9M
- Narendranath EpperlaColumbus$3.6M
- Lapo AlinariColumbus$3.1M
- Spero CatalandColumbus$2.8M
- Seema BhatColumbus$2.7M
- Nicole GrieselhuberColumbus$2.5M
- David BondColumbus$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.